GCF IL-17 Levels and Oxidative Status of Smoking and Non-smoking Individuals With Periodontitis

Smoking Effects on GCF GCF IL-17A AND IL-17 Levels and Oxidative Status of Patients Receiving Periodontal Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04115176

Acronym

GCF

Enrollment

Registered

2019-10-03

Start date

2017-10-10

Completion date

2019-07-10

Last updated

2019-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis, Smoking, Cigarette

Keywords

chronic periodontitis, smoking,, periodontal treatment,, IL-17,, oxidative stress

Brief summary

This study was performed to evaluate the effects of both periodontal treatment and smoking on the gingival crevicular fluid(GCF) levels of interleukin (IL)-17A, IL-17E, Total oxidative stress(TOS) and total antioxidant capasity(TAOC) in smoking and non-smoking patients with severe chronic periodontitis. Systemically healthy 15 smoker,15 non-smoker with chronic periodontitis were attended for the study. Periodontal status were determined by recording periodontal clinical measurements. GCF samples were collected at the baseline, at the end of initial periodontal treatment and 4 weeks after periodontal flap surgery. The data were tested statistically by the Student t and paired sample t tests.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to 60 Years

Healthy volunteers

Inclusion criteria

* individuals aged ˃35 years and having ≥16 teeth diagnosed as chronic periodontitis * not received any periodontal therapy within the previous 6 months; * not received antibiotic/anti-inflammatory drug treatment within the previous 6 months.

Exclusion criteria

* receiving medical treatment for cancer, rheumatoid arthritis, diabetes mellitus, cardiovascular disease, or any other systemic disease; * being pregnant or being in the period of menopause or lactation; * receiving any drug therapy that might affect the clinical characteristics of periodontitis; * usage of systemic antimicrobials during the 6 weeks prior to data collection

Design outcomes

Primary

Measure	Time frame	Description
GCF IL-17A VOLUME	GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .	IL-17A is a cytokine present in gingival crevicular fluid. Its volume calculated as microliter and changes due to inflammation caused by periodontal disease.
GCF IL-17E VOLUME	GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .	IL-17E is a cytokine present in gingival crevicular fluid. Its volume calculated as microliter and changes due to inflammation caused by periodontal disease.
GCF TOTAL OXIDATIVE STRESS (TOS) LEVEL	GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .	TOS is the measurement of oxidative stress amount and given as mmol/L unit. Its amount changes due to inflammation caused by periodontal disease.
GCF TOTAL ANTIOXIDANT CAPASITY (TAOC)	GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .	TAOC is the antioxidant amount measured and given as μmol H2O2 Eq/L unit. Its amount changes due to inflammation caused by periodontal disease.

Countries

Turkey (Türkiye)

Outcome results